Depo Provera and cancer risk
- effect on breast cancer risk - less than or similar to the combined oral contraceptive pill (1)
- there is possibly a weak association between current use of DMPA and breast cancer. Any increased risk is likely to be small and reduce with time after stopping (2)
- there is possibly a weak association between current use of DMPA and breast cancer. Any increased risk is likely to be small and reduce with time after stopping (2)
- not associated with increased risk of ovarian, cervical or liver cancer (1)
- protective effect against endometrial cancer (five-fold - relative risk 0.2) - this protective effect continues for up to eight years after discontinuation (1)
- there is a weak association between cervical cancer and use of DMPA for 5 years or longer. Any increased risk appears to reduce with time after stopping and could be due to confounding factors (2)
Reference:
- (1) Prescriber (1999), 10 (16), 29-41.
- (2) FSRH (December 2014). Progestogen-only injection contraception.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.